**Enhanced Derivatives of Nisin**

Teagasc and UCC are seeking commercial partners within the food and pharmaceutical industries to further develop and commercialise superior derivatives of nisin bacteriocins, for applications in the food areas of bio-preservation and medical devices.

**Summary**

Teagasc and UCC have developed foodgrade derivatives of nisin A, and producers thereof, with greatly enhanced antimicrobial activity. This offers potential in a greater range of food products and other products within medical/medical device areas, when compared to commercial nisin A.

**Problem Addressed**

Nisin A is an antimicrobial peptide which is used as a natural food biopreservative in over 50 countries. Nisin and nisin-producing foodgrade *Lactococci* are extensively used in food nisin is the only peptide to have been added to the European food additive list (E234) and approved by the US Food and Drug Agency (FDA) and World Health Organisation. Despite its success, its application is limited in some instances due to its relative inactivity against particular target species and strains and/or its poor activity at non-acidic pHs.

**Solution**

Recently developed foodgrade derivatives of nisin and its producers have been found to display greatly enhanced antimicrobial activity against problematic pathogenic and spoilage microbes. They are also active at non-acidic pHs and are effective not only against a broader range of gram positive bacteria but also some gram negative bacteria. With the added benefit of being effective at non-acidic pH, this ingredient has the potential to be applied in a greater range of food products. The availability of enhanced forms of nisin could result in the replacement of nisin A and make other applications a reality.

**Competitive Advantage of Technology**

1. Enhanced antimicrobial activity.
2. Active at non-acidic pHs.
3. Extended applications of nisin.

**Opportunity**

This technology would be of interest to companies in the fields of food biopreservatives and medical devices and it is currently being evaluated by a company in the animal health field. Companies are invited to discuss this technology with a view to further development in the following areas:

- Demonstration of safety of variants.
- Demonstration of shelflife extension properties.
- Development of foodgrade applications.
- Scale-up manufacturing.

**Intellectual Property Status**

Patent applications on the various nisin derivatives have been filed by Teagasc and UCC.

**Partners**

Funding

**How to Proceed:**

For further information contact:

Miriam Walsh
Tel: +353 (0)59 9183477
Email: miriam.walsh@teagasc.ie